BrainCool AB (publ) - market clearance in Europe for Cooral® Systems to prevent Oral Mukosit
BrainCool AB (publ) CE-marks Cooral® Systems, which means that market clearance for ehe European market is now in place, to prevent oral mucositis (OM). OM is a serious side effect that can arise from radiation and chemotherapy treatment of various cancers. The approval for the Cooral® System is as an invasive product, which paves the way for a market launch as clinical data is now submitted for presentation at the ESMO conference on 18-22 September (European Society for Medical Oncology, reference 1). Cooral® Systems has been assessed in a Nordic clinical trial on a total of 180